Related Experiment Video
Updated: Aug 11, 2026
Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
Comparison of G-protein coupled receptor desensitization-related beta-arrestin redistribution using confocal and
Dorothea Haasen1, Michael Wolff, Martin J Valler
1Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Integrated Lead Discovery, Birkendorfer Str. 65, D-88397 Biberach, Germany.
Abstract:
High Content Screening (HCS), a combination of fluorescence microscopic imaging and automated image analysis, has become a frequently applied tool to study test compound effects in cellular disease-modelling systems. In this work, we compared a confocal and a non-confocal cellular HCS system, the IN Cell Analyzers(1) 3,000 and 1,000, respectively. As a cellular model system we used the Transfluor technology in the 384-well microtiter plate (MTP) format. The Transfluor HCS assay for G-protein coupled receptor (GPCR) activation is based on the recruitment of a green fluorescent protein-labelled arrestin (ArrGFP) from the cytosol to the plasma membrane. We investigated two GPCRs, the wild-type (wt) beta2 adrenergic receptor (beta2AR) and the beta2AR-enhanced (E), a C-terminally mutated receptor with a higher affinity to arrestin. Upon agonist stimulation, the beta2AR-wt induced the redistribution of ArrGFP to coated pits, the beta2AR-E maintained the interaction with ArrGFP down to the formation of endocytic vesicles. Our findings reveal that the assay is feasible on both instruments, with sufficiently robust Z' statistics. Improved Z' statistics, though, are achieved with the confocal system, particularly in case of weak signals. Moreover, throughput is dramatically higher for the IN Cell Analyzer 3,000. We conclude that, depending on the needs for throughput and assay biology, either instrument may fulfil a successful role in the drug discovery process. Confocal optics, however, provide a better basis for the detection of smaller subcellular structures with lower fluorescence intensity.
Insights
This study compares confocal and non-confocal High Content Screening systems using a Transfluor assay for G-protein coupled receptor activation. Confocal systems offer improved sensitivity and Z
Area of Science:
- Cellular biology and drug discovery
- High Content Screening (HCS) assay development
- G-protein coupled receptor (GPCR) signaling
Background:
- High Content Screening (HCS) combines microscopy and image analysis for cellular studies.
- Transfluor technology utilizes arrestin-green fluorescent protein (ArrGFP) recruitment to monitor GPCR activation.
- Comparing different HCS systems is crucial for optimizing drug discovery workflows.
Purpose of the Study:
- To compare the performance of a confocal (IN Cell Analyzer 3,000) and a non-confocal (IN Cell Analyzer 1,000) HCS system.
- To evaluate the Transfluor HCS assay for GPCR activation using two distinct beta2 adrenergic receptor variants.
- To assess assay feasibility, robustness (Z' statistics), and throughput on both HCS platforms.
Main Methods:
- Utilized the Transfluor assay in a 384-well microtiter plate format with wild-type (wt) and enhanced (E) beta2 adrenergic receptors.
- Measured agonist-induced recruitment of ArrGFP to the plasma membrane using both confocal and non-confocal HCS systems.
- Analyzed Z' statistics and throughput for each instrument and receptor variant.
Main Results:
- The Transfluor assay is feasible on both IN Cell Analyzers, demonstrating robust Z' statistics.
- The confocal system (IN Cell Analyzer 3,000) achieved improved Z' statistics, especially for weak signals.
- The IN Cell Analyzer 3,000 exhibited significantly higher throughput compared to the IN Cell Analyzer 1,000.
Conclusions:
- Both confocal and non-confocal HCS systems can successfully support the Transfluor GPCR activation assay.
- Confocal microscopy provides enhanced detection capabilities for subcellular structures and low-intensity signals.
- The choice of HCS system depends on specific needs for throughput and assay sensitivity in drug discovery.
